{
    "clinical_study": {
        "@rank": "41873", 
        "arm_group": [
            {
                "arm_group_label": "direct thrombin inhibition", 
                "arm_group_type": "Experimental", 
                "description": "dabigatran 110 mg BID, po argatroban (0.5 - 1 \u00b5g/kg/min) if peroral therapy is not possible"
            }, 
            {
                "arm_group_label": "enoxaparin", 
                "arm_group_type": "Active Comparator", 
                "description": "enoxaparin 40 mg od, sc"
            }
        ], 
        "brief_summary": {
            "textblock": "Safety and efficacy of direct thrombin inhibitors versus enoxaparin in patients with\n      staphylococcus aureus bacteraemia.\n\n      The study hypothesizes that inhibition of the coagulase-activity of S. aureus by direct\n      thrombin inhibitors is safe and translates into a better outcome of patients with S. aureus\n      bacteremia."
        }, 
        "brief_title": "Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia", 
        "condition": "Staphylococcus Aureus Bacteraemia", 
        "condition_browse": {
            "mesh_term": [
                "Bacteremia", 
                "Staphylococcal Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Positive blood culture for stahylococcus aureus\n\n          -  Symptoms or signs of infection\n\n          -  Indication for thromboprophylaxis\n\n        Exclusion Criteria:\n\n          -  Contraindication for thromboprophylaxis\n\n          -  Significant active bleeding or risk of excessive bleeding\n\n          -  Heparine-induced thrombocytopenia\n\n          -  Severe liver and kidney disease\n\n          -  Pregnancy and lactation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911624", 
            "org_study_id": "S54881"
        }, 
        "intervention": [
            {
                "arm_group_label": "direct thrombin inhibition", 
                "intervention_name": "direct thrombin inhibition", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "enoxaparin", 
                "intervention_name": "enoxaparin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Thrombin", 
                "Antithrombin Proteins", 
                "Enoxaparin", 
                "Antithrombins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leuven", 
                    "country": "Belgium", 
                    "zip": "3000"
                }, 
                "name": "KUleuven/UZ Gasthuisberg"
            }, 
            "investigator": {
                "last_name": "Peter Verhamme, Prof.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia. A Prospective Randomized Controlled Academic Single-centre Feasibility Study.", 
        "other_outcome": [
            {
                "measure": "Laboratory markers of coagulation", 
                "safety_issue": "No", 
                "time_frame": "From randomization until D7-10"
            }, 
            {
                "measure": "Laboratory markers of inflammation", 
                "safety_issue": "No", 
                "time_frame": "From randomization until D7-10"
            }, 
            {
                "measure": "Clinical outcomes after S. aureus bacteremia", 
                "safety_issue": "No", 
                "time_frame": "From randomization until M3"
            }
        ], 
        "overall_contact": {
            "email": "Peter.verhamme@uzleuven.be", 
            "last_name": "Peter Verhamme, PI", 
            "phone": "003216343491"
        }, 
        "overall_contact_backup": {
            "email": "Barbara.debaveye@uzleuven.be", 
            "last_name": "Barbara Debaveye, study coordinator", 
            "phone": "003216343491"
        }, 
        "overall_official": {
            "affiliation": "Bloedings-en vaatziekten, UZ Gasthuisberg", 
            "last_name": "Peter Verhamme, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Primary Safety Outcome is the occurence of clinically-relevant bleeding events", 
            "safety_issue": "Yes", 
            "time_frame": "From date of randomization up to end of study drug + 3 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911624"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universitaire Ziekenhuizen Leuven", 
            "investigator_full_name": "Peter Verhamme", 
            "investigator_title": "Prof.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "as documented with a PET-CTscan in eligible patients on D7-10 or clinically-overt metastatic infectious foci", 
            "measure": "The primary efficacy outcome is the occurence of metastatic infection", 
            "safety_issue": "Yes", 
            "time_frame": "From randomization until month 3"
        }, 
        "source": "Universitaire Ziekenhuizen Leuven", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitaire Ziekenhuizen Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}